June 30, 2025

Breakthrough Device Approvals Outpacing Data

Many FDA-authorized breakthrough therapeutic devices may lack robust clinical testing.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

Could Vertigo Be Signaling Something More?

Dizziness may be more than a balance issue—research links vestibular disorders to significantly increased mental health risks.

Conexiant

June 27, 2025

Does Erenumab Prevent Chronic Cluster Headaches?

Trial finds erenumab no more effective than placebo in preventing chronic cluster headache attacks.

Conexiant

June 27, 2025

MASLD Linked to Sudden Hearing Loss

New research links a common metabolic liver condition in older adults to elevated risk of sudden hearing loss, highlighting potential implications for screening and prevention.

Conexiant

June 25, 2025

Blood Marker May Predict Faster Brain Decline

A new study found that higher triglyceride-glucose index levels, a marker of insulin resistance, were linked to faster cognitive decline in early Alzheimer's, suggesting potential for improved risk assessment in clinical settings.

Conexiant

June 25, 2025

Nighttime Heart Rhythms Predict Brain Disorders

A large Swiss study found that nighttime heart rate patterns may predict future risk for brain and psychiatric disorders, while traditional sleep structure measures were less informative.

Conexiant

June 24, 2025

Cannabis Use Linked to Higher Heart Risks

A new systematic review and meta-analysis found that cannabis use is associated with an increased risk of major adverse cardiovascular events—including acute coronary syndrome, stroke, and cardiovascular death—based on data from more than 432 million individuals in 24 observational studies.

Conexiant

June 24, 2025

Liraglutide Linked to Fewer Migraine Days

A small observational study found that liraglutide, a GLP-1 receptor agonist typically used to treat diabetes and support weight loss, significantly reduced migraine frequency in adults with a BMI of 30 or higher—independent of weight change.

Conexiant